Literature DB >> 16163625

Artemisinin-based combination treatment for malaria in Africa: no perfect solutions.

Christopher J M Whitty, Sarah G Staedke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16163625     DOI： 10.1086/444464

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  5 in total

1.  Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children.

Authors:  Michael Nambozi; Jean-Pierre Van Geertruyden; Sebastian Hachizovu; Mike Chaponda; Doreen Mukwamataba; Modest Mulenga; David Ubben; Umberto D'Alessandro
Journal:  Malar J       Date:  2011-02-28       Impact factor: 2.979

Review 2.  Monitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania.

Authors:  Alex Shayo; Joram Buza; Deus S Ishengoma
Journal:  Malar J       Date:  2015-03-29       Impact factor: 2.979

3.  Xylopic acid-amodiaquine and xylopic acid-artesunate combinations are effective in managing malaria in Plasmodium berghei-infected mice.

Authors:  Silas Acheampong Osei; Robert Peter Biney; Ernest Obese; Mary Atta-Panyi Agbenyeku; Isaac Yaw Attah; Elvis Ofori Ameyaw; Johnson Nyarko Boampong
Journal:  Malar J       Date:  2021-02-25       Impact factor: 2.979

4.  Artesunate Plus Amodiaquine (AS+AQ) Versus Artemether -Lumefantrine (AL) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Sub-Saharan Africa-A Meta-Analysis.

Authors:  Shaibu O Bello; Aminu Chika; Jimoh O Abdulgafar
Journal:  Afr J Infect Dis       Date:  2010

5.  Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial.

Authors:  Birgit Schramm; Parastou Valeh; Elisabeth Baudin; Charles S Mazinda; Richard Smith; Loretxu Pinoges; Mehul Dhorda; Yap Boum; Timothy Sundaygar; Yah M Zolia; Joel J Jones; Eric Comte; Pascal Houzé; Vincent Jullien; Gwenaelle Carn; Jean-René Kiechel; Elizabeth A Ashley; Philippe J Guérin
Journal:  Malar J       Date:  2013-07-17       Impact factor: 2.979
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.